HAOHAI BIOTEC (06826) announced plans to enhance the efficiency of raised capital usage by deploying temporarily idle funds for cash management. The company intends to allocate up to RMB 300 million (inclusive) of temporarily idle proceeds, ensuring no impact on ongoing fundraising projects, capital safety, or diversion from intended purposes. This initiative aims to boost corporate earnings and deliver greater returns to shareholders. The approved fund utilization period spans 12 months from board approval, allowing cyclical reinvestment within the specified quota and timeframe.